Rallis Chris A's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Dec 28, 2023
- Accession no.
- 0001104659-23-130042
- Filed
- Dec 28, 2023
- Trade date
- Dec 26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $15.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rallis Chris ACIK 0001185945 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | Common Shares | SSaleDisposed | −1,390 | $10.90 | −$15,151 | 44,788 | Direct | |
| Dec 26, 2023 | Common Shares | MOption exerciseAcquired | +3,144 | $1.59 | +$4,998.96 | 46,178 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | Options | MOption exerciseDisposed | −3,144 | $1.59 | −$4,998.96 | 184,168 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.